Positive clinical trial results of investigational thrombocytopenia agent

Armen Hareyan's picture
Advertisement

AKR-501 is a promising member of a new class of agents called, "TPO receptor agonists" that is now in Phase II clinical development. It is an investigational orally administered drug being developed by AkaRx, Inc. intended to mimic the biologic effect of thrombopoietin, a growth factor that stimulates production of platelets.

At the American Society of Hematology meeting, results from two Phase I clinical research trials were presented. These data in healthy volunteers showed that AKR-501 produced a 50% increase or greater over the baseline platelet count. AKR-501 is the first oral drug in its class to show these platelet increases with a single dose. In the single dose study this was achieved at the 100 mg dose. In all volunteers given multiple doses of either 10 mg or 20 mg for 10

Advertisement